Navigation Links
SemBioSys provides update on insulin program
Date:4/1/2009

CALGARY, April 1 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, provides an update on its proprietary plant-produced recombinant human insulin program. In December 2008, SemBioSys announced that MannKind Corporation purchased a non-refundable option to license rights to SemBioSys' proprietary plant-produced recombinant human insulin to be used primarily for AFRESA(TM), MannKind's ultra-rapid acting insulin product. At the time the option was taken, MannKind had completed diligence related to the SemBioSys insulin program and final written agreements had been prepared for execution, were the option to be exercised. In March 2009, MannKind announced that it had entered into agreements with Pfizer Inc. "to purchase Pfizer's insulin facility at Industriepark Hoechst, Frankfurt am Main, Germany and assets related to the production of bulk insulin, including the relevant real property rights, the production equipment, a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery." The option period for SemBioSys' agreement with MannKind expired yesterday without action and SemBioSys is now free to execute agreements relating to its insulin program with other parties.

Also in March 2009, SemBioSys reported results from the Phase I/II trial of its recombinant human insulin (SBS-1000) in human volunteers. SBS-1000 was shown to be bioequivalent to Eli Lilly's Humulin(R) R, a widely-used human insulin in North America.

"Based on prior discussions with third parties, we believe that our recent clinical trial results position us well to continue and expand our partnership discussions," said James Szarko, Chief Executive Officer of SemBioSys. "While the MannKind option was attractive from a timing point of view, and provided a valuable cash infusion, additional partnering options may be open to us now that we have positive clinic
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
2. SemBioSys announces senior management changes
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. SemBioSys begins phase I/II trial of insulin produced in plant seeds
5. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
6. SemBioSys announces second quarter 2008 financial and operational results
7. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
8. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
9. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
10. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... (PRWEB) December 13, 2014 According to ... million people between now and 2030." If a population ... the seventh most populous state in the country. , ... gathering at the Future of North Carolina Forum on ... Do we have the necessary infrastructure in place? Enough ...
(Date:12/13/2014)... Texas , Dec. 12, 2014  Vermillion, Inc. ... announced today the appointments of Veronica G. H. ... to the Company,s Board of Directors, bringing the total ... independent. Jim LaFrance , Chairman, ... am tremendously pleased to announce the appointments of Veronica ...
(Date:12/13/2014)... ROCHESTER, N.Y. , Dec. 12, 2014 ... engaged in the discovery and development of ... neurodegenerative diseases, today announced publication of a ... microglia, and inhibits remyelination in neurodegenerative disease" ... journal Neurobiology of Disease*.  The publication highlights ...
(Date:12/12/2014)... December 11, 2014 InSphero AG, the ... efficacy testing, announced today that data presented recently by ... microtissues as a more predictive model system for assessment ... the 2nd Annual Functional Analysis and Screening Technologies ... the response of InSphero’s 3D InSight™ Human Liver ...
Breaking Biology Technology:North Carolina Chamber of Commerce: Asking Questions & Gathering Answers with a Futurist 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 2Vermillion Strengthens Board of Directors with Appointments of Veronica Jordan, Ph.D., and David Schreiber 3Vaccinex announces publication of preclinical studies with an anti-SEMA4D antibody in animal models of neuroinflammatory and demyelinating disease 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 2Enhanced Sensitivity of InSphero 3D Liver Microtissues Highlighted at Annual Screening Congress 3
... (Nasdaq: FOLD ) today announced the election ... Directors. Dr. Barer currently serves as Chairman and ... industry veteran, Dr. Barer brings over 20 years of ... respected leader who has helped transform Celgene into one ...
... Inc.,(Nasdaq: NUVO ) today announced that ... Nuvelo Common Stock pursuant to the merger agreement ... biopharma and a Nuvelo,subsidiary. Nuvelo,s stockholders also voted ... 2009, to solicit additional proxies in,favor of a ...
... QUEBEC, Jan. 7 /PRNewswire-FirstCall/ - Victhom Human Bionics ... participate in the,OneMedPlace Finance Forum in San Francisco, ... Chief Operating Officer of Victhom,s Neurobionix division, will,be ... Pacific Time, at the Sir,Francis Drake Hotel at ...
Cached Biology Technology:Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors 2Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 2Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 3Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 4Nuvelo Shareholders Approve Issuance of Common Stock Pursuant to Merger Agreement With ARCA biopharma 5Victhom to Participate in the OneMedPlace Finance Forum 2
(Date:12/5/2014)... Dec. 4, 2014  Tute Genomics, a leader in ... in Series A1 funding led by UK-based Eurovestech. Peak ... in the investment round. "We are at ... adopts next-generation sequencing and seeks new approaches for the ... Robison , MD MBA, and CEO of Tute Genomics. ...
(Date:12/3/2014)... 2, 2014 As part of our commitment ... is pleased to announce the release of a new ... collect the workforce data that they need. ... left by existing readers. Many such devices have serious ... modern technology. Older models force users to navigate numerous ...
(Date:11/21/2014)... Strict laws against distracted driving and the ... American and European automotive sector towards gesture recognition technologies. ... that are intuitive and able to retrieve information with ... New analysis from Frost & Sullivan,s Strategic ... Europe and North America ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... organisms tend to live longer if their intake of ... fruit flies, just the smell of food can have ... for decades that restricted dietary intake can increase the ... this is not understood. Short-lived organisms like the fruit ...
... for cancer is one step closer this week with ... the new Wesley Research Institute Tissue Bank. , The ... Queensland to provide a widely available and diversified collection ... unravel the cause, progression and potential treatment for cancer ...
... evidence suggests that the risk of HIV transmission may ... According to a study published in the April 1 ... online, early infection accounted for nearly half of all ... of Quebec, Canada. , Bluma Brenner, PhD, and Mark ...
Cached Biology News:Researchers find link between food odors and lifespan in fruit flies 2Researchers find link between food odors and lifespan in fruit flies 3Researchers find link between food odors and lifespan in fruit flies 4Researchers find link between food odors and lifespan in fruit flies 5Cure for cancer one step closer 2Risk of HIV transmission highest early in infection 2
... The ProteoExtract™ Protein Precipitation Kit is ... of proteins from aqueous samples. Proteomics ... the presence of non-protein impurities such ... the protein sample that interfere with ...
... luminometer provides the sensitivity and versatility you ... digital photon counting with selected photomultipliers ensure ... demands. Equipped with up to 2 reagent ... reporter gene assays as well as other ...
... high-speed analytical techniques, the AutoTrace SPE is a powerful, high-throughput workstation dedicated specifically ... loading and elution steps for large volumes aqueous solution extractions (up to 2000ml's). ... ... ...
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
Biology Products: